The Decline in Invasive Pneumococcal Disease

Pediatrics

Volumn 113, Issue 3 I, 2004, Pages 617-618

  Pelton, Stephen I ^a  

^a BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 VALENT PNEUMOCOCCAL CONJUGATE VACCINE; CARRIER PROTEIN; CEFTRIAXONE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE; UNCLASSIFIED DRUG; VANCOMYCIN;

HAEMOPHILUS INFLUENZAE TYPE A; HUMAN; IMMUNOGENICITY; INCIDENCE; INFLUENZA; NOTE; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

DEVELOPING COUNTRIES; DRUG RESISTANCE, BACTERIAL; HUMANS; MENINGOCOCCAL VACCINES; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; WORLD HEALTH;

EID: 1442348287     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.113.3.617     Document Type: Note

References (5)

1. Kaplan SL, Mason EO Jr, Wald ER, et al. Decrease of Invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics. 2004;113:443-449
2. Progress toward eliminating Haemophilus influenzae type b disease among infants and children-United States, 1987-1997. MMWR Morb Mortal Wkly Rep. 1998;47:993-998
3. From the Centers for Disease Control and Prevention. Updated recommendations on the use of pneumococcal conjugate vaccine in a setting of vaccine shortage-Advisory Committee on Immunization Practices. JAMA. 2002;287:833-834
4. Hausdorff WP, Siber G, Paradiso PR. Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. Lancet. 2001;357:950-952
5. Pneumococcal vaccines. WHO position paper. Wkly Epidemiol Rec. 1999;74:177-183. Available at: www.who.int/wer/pdf/1999/wer7423.pdf